Drug type: Methotrexate is an anti-cancer "antineoplastic" or "cytotoxic" chemotherapy drug. This medication is classified as an "antimetabolite. Note: If a drug has been approved for one use, physicians may elect to use this same drug for other problems if they believe it may be helpful.
Polymer micelles have emerged as promising carriers for controlled release applications, however, several limitations of micelle-based drug delivery have also been reported. The synthesized polymer was formulated as micelles using a dialysis method and loaded with the anti-inflammatory and anti-cancer drug methotrexate MTX. The micellar cores were subsequently crosslinked at their pendent azides by a redox-responsive bis alkyne.
Expression of these receptors allows for treatment with endocrine or targeted therapies in clinical cases 3 — 5which are not useful for clinical TNBC cell treatment 6 — 8. Therefore, it is important to develop new methods for suppressing TNBC cell growth and survival. Methotrexate MTX is a well-known antagonist of folic acid 910 and has been used widely for rheumatoid arthritis treatment 11
This phase II trial studies how well high-dose methotrexate works in treating patients with breast cancer that has spread to the thin layers of tissue that cover and protect the brain and spinal cord called leptomeninges leptomeningeal metastasis. Drugs used in chemotherapy, such as methotrexate, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Patients receive high-dose methotrexate intravenously IV over 4 hours on day 1. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity.
Study record managers: refer to the Data Element Definitions if submitting registration or results information. Management of LMD in patients with metastatic breast cancer is an area of unmet clinical need. Increased survival in the era of hormonal and HER2 directed therapies has further heightened the need for more effective therapies against the late complications of metastatic disease.
This paper chronicles developments in the laboratory of Dr. Bruce Chabner during the period Initial work demonstrated that methotrexate is taken up by human breast cancer cells by a high-affinity, carrier-mediated, energy-dependent transport system similar to that described in murine leukemia cells.
Methotrexate MTXformerly known as amethopterinis a chemotherapy agent and immune system suppressant. Common side effects include nausea, feeling tired, fever, increased risk of infection, low white blood cell countsand breakdown of the skin inside the mouth. Methotrexate was made in and initially came into medical use to treat cancer, as it was less toxic than the then-current treatments.
Background: Oral metronomic chemotherapy is a therapeutic option which is particularly attractive due to its ease of administration and low toxic burden. Its mechanism of action probably involves antiangiogenetic effect rather than a classical antiproliferative effect like standard maximally tolerated dose-based regimens. Patients and Methods: A retrospective analysis of 61 patients with advanced breast carcinoma was carried out with the aim of reporting activity in terms of response rate, control of tumor-related symptoms, outcome, and toxicity.